Aquestive Therapeutics, Inc. (AQST)
4.055
+0.08
(+2.14%)
USD |
NASDAQ |
Oct 27, 16:00
4.055
0.00 (0.00%)
After-Hours: 20:00
Aquestive Therapeutics Cash from Operations (Quarterly) : -9.441M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.441M |
| March 31, 2026 | -14.81M |
| December 31, 2025 | -8.469M |
| September 30, 2025 | -12.65M |
| June 30, 2025 | -7.914M |
| March 31, 2025 | -23.40M |
| December 31, 2024 | -6.489M |
| September 30, 2024 | -11.88M |
| June 30, 2024 | -7.006M |
| March 31, 2024 | -10.38M |
| December 31, 2023 | -4.942M |
| September 30, 2023 | -2.347M |
| June 30, 2023 | -7.907M |
| March 31, 2023 | 8.816M |
| December 31, 2022 | 8.446M |
| September 30, 2022 | 2.809M |
| June 30, 2022 | -6.562M |
| March 31, 2022 | -14.48M |
| December 31, 2021 | -8.061M |
| Date | Value |
|---|---|
| September 30, 2021 | -9.065M |
| June 30, 2021 | -1.756M |
| March 31, 2021 | -14.10M |
| December 31, 2020 | -13.51M |
| September 30, 2020 | -8.313M |
| June 30, 2020 | -9.997M |
| March 31, 2020 | -13.64M |
| December 31, 2019 | -10.58M |
| September 30, 2019 | -14.79M |
| June 30, 2019 | -17.17M |
| March 31, 2019 | -17.68M |
| December 31, 2018 | -7.58M |
| September 30, 2018 | -9.947M |
| June 30, 2018 | -1.017M |
| March 31, 2018 | 0.785M |
| December 31, 2017 | -7.409M |
| September 30, 2017 | 15.63M |
| June 30, 2017 | -6.305M |
| March 31, 2017 | 3.908M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Eton Pharmaceuticals, Inc. | 7.255M |
| LENZ Therapeutics, Inc. | -38.71M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.212M |
| Cash from Financing (Quarterly) | -2.591M |
| Free Cash Flow | -45.95M |
| Free Cash Flow Per Share (Quarterly) | -0.0772 |
| Free Cash Flow to Equity (Quarterly) | -25.16M |
| Free Cash Flow to Firm (Quarterly) | -5.813M |
| Free Cash Flow Yield | -9.44% |